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RESUMEN
La selección de especies animales óptimas que puedan servir para estudiar el me-
tabolismo de fármacos en humanos es todavía un gran reto en el programa de des-
arrollo de fármacos. Las especies utilizadas en estudios de metabolismo deberían tam-
bién incluir parámetros de toxicidad relacionados con el metabolismo. El uso de
proteínas CYP recombinantes humanas y de sistemas de expresión no puede resolver
este problema. Las especies más usadas en estudios metabólicos son: ratón, rata, co-
nejo, perro y mono, y en menor grado cobayas y hamsters. Todos ellos son de algu-
na manera defectivos en su perfil de CYP cuando se comparan al humano. Por ejem-
plo, la presencia del enzima CYP1A2 en mono es controvertida; las actividades
marcadoras clásicas de los CYP2C y CYP2E en perro están cuestionadas; el CYP2A
de hígado de rata no cataliza la reacción de la 7-hidroxilación de la cumarina; la
CYP2D de cerdo no cataliza la reacción de la hidroxilación de la debrisoquina y di-
versas otras formas CYP tienen pesos moleculares diferentes a los CYP humanos o
de rata. Excepto en el hombre y la rata, las proporciones relativas de diversas formas
CYP a nivel basal no han sido investigadas y cuantificadas en otras especies. Aunque
los primates no humanos se han considerado el mejor modelo para estudiar el meta-
bolismo de fármacos en humanos, debido a rezones éticas el uso de monos puede no
ser la primera opción para el estudio in vivo de las características metabólicas de una
nueva entidad química. Debido a las diferencias dependientes de las especies en la es-
tructura primaria de las distintas formas CYP y en la expresion génica que conduce
las cascadas reguladoras, pueden encontrarse notables diferencias en el nivel basal de
la expresión de CYP en su inducibilidad y en las propiedades de unión a sustratos,
inhibidores y anticuerpos. Por tanto, el principal obstáculo en la interpretación de los
resultados asociados a CYP de una especie a otra es la carencia de conocimientos bá-
sicos necesarios para hacer el diagnóstico en otras especies. 
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1. ABSTRACT
Selection of the optimal animal species to mimic drug metabolism in
man is still a big challenge in a drug development program. The species
used in metabolism studies should also pick up possible metabolism-lin-
ked toxicity end points. The use of human recombinant CYP proteins and
expression systems could not resolve that specific question. The mostly
used species in metabolism studies are mouse, rat, rabbit, dog and mon-
key, lesser extent guinea pig and hamster. All of them are somehow “de-
fective” in their CYP profile compared to man. For instance the presen-
ce of CYP1A2 enzyme in cynomolgous monkeys is controversial;
classical marker activities for CYP2C and CYP2E in dogs are contested;
rat hepatic CYP2A does not catalyze coumarin7-hydroxylation reaction,
pig CYP2D does not catalyze debrisoquine hydroxylation reaction and
several other CYP forms have different molecular weight compared to rat
and human counterpart. Except man and rat, relative proportions of va-
rious CYP forms at basal level have not been investigated and quantita-
ted for other species. Although non-human primates have considered to
be the “best fit” models to mimic drug metabolism in man still due to
ethical reasons the use of monkeys may not be the first option to study
the metabolic characteristics of a new chemical entity in vivo. Due to spe-
cies-dependent differences in the primary structure of distinct CYP forms
and differences in the gene expression guiding regulatory cascades, re-
markable differences in the basal CYP expression level, inducibility, subs-
trate, inhibitor and antibody binding properties can be found. Except man
and rat, relative proportions of various CYP forms at basal level have not
been investigated and quantitated for other species. Therefore, the main
obstacle in interpretation of CYP-associated results from one species to
the other is the lack of basic knowledge in “is the finding diagnostic for
other species”.
2. INTRODUCTION
In a drug development program, or drug research in general, species-
dependent differences in the expression of drug metabolizing enzymes and
species-dependent differences in substrate specificities and responses to
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diagnostic chemical inhibitors is still a big problem. Although human re-
combinant enzymes offer a considerable straightforward approach to study
and detect metabolic characteristics in human tissues and organelles still
the main obstacle is: How to select the optimal species to mimic drug me-
tabolism in man so that in following toxicological studies relevant, possibly
metabolism-linked toxicity end points, will be picked up. In order to over-
come with this question I’ll highlight an up to-date comparative overview
based on published literature on cytochrome P450 (CYP) linked species-
dependent characteristics in terms of «major» xenobiotic-metabolizing CYP
enzymes in rodents, rabbit, dogs, pigs, non-human primates and man. Al-
though extrahepatic CYP-mediated metabolism can be of great significan-
ce, the hepatic drug metabolism is still the predominant factor in species-
dependent differences. Therefore, the main focus is in hepatic CYP forms.
All animal CYP genes and accession numbers are available at Internet at
Dr Nelson’s web pages (http://drnelson.utmem.edu/CytochromeP450.html;
www.imm.ki.se/cypalleles/www.icgeb.org/~p450srv/P450Nom_Animals).
This review does not go in depth into each CYP form, rather a more ge-
neral overview is given.
Previously some outstanding articles under the similar title have been
published [1-4] which should be read together with the present overview.
Already at this point I have to emphasize that in the literature there are not
very many papers in which this topic has been comparatively studied with
relevant species and using validated methodology. This bias have to be kept
in mind when reading the text and comparing catalytic activity data in the
Tables included.
3. XENOBIOTIC METABOLIZING CYP FAMILIES - GENERAL
BACKGROUND AND PRESENT REGULATORY PLATFORM
3.1. Cytochrome P450 content and conditions affecting metabolic
activities
According to Shimada and coworkers [5] and Stevens and cowor-
kers [6] the species-dependent differences can be identified already from
the total microsomal P450 content (Table 1) which is 3-4 fold higher in
monkeys, two fold higher in rat compared to human value, and within
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human value in beagle dog microsomes [7]. In addition, in man disea-
ses and clinical drug therapies may significantly affect or increase to-
tal P450 content and metabolizing activities and drug cleareance, thus
complicating species selection. Consequently, total P450 content in hu-
man microsomes can rise up to 1 nmol/mg protein as was the clinical
case after a long term phenobarbital therapy (Table 1). As a general re-
mark from Table 1 and the others presented in the article, remarkable
laboratory-dependent differences in the total P450 content and cataly-
tic activities can be found. Obvious reasons for that are interlaboratory
differences in the quality and processing methodology of the starting
material. The best indicator for such differences is the human value,
which —if low— reflects the differences of the quality of starting ma-
terial (delay in starting preparation of subcellular organelles, methodo-
logies used, etc).
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TABLA 1
Hepatic microsomal CYP450 content in different species
Species P450 Content
pmol/mg protein
Human (Our Lab) 400 up to 1000
Human 307 ± 160
Monkey 1030 ± 106
Dog 386 ± 36
Pig 488 ± 83 (f)
Minipig 821 ± 183 (f)
Guinea pig 1235 ± 95
Rabbit 681 + 36
Rat 673 ± 50
Mouse 719 + 41
data from [5, 35, 36, 77]; f, female;
Based on in vitro and in vivo data immunomodulators (see [8]) and in-
flammatory diseases [9-11] downregulate CYP expression. On the other
hand type 1 diabetes in children has been demonstrated to enhance antipy-
rine clearance and drug metabolism in children [12]. Moreover, in experi-
mental and clinical cases of hepatic injuries individual total CYP profile
may change [13-15]. Interestingly, except man and rat relative proportions
of various CYP forms at basal level have not been investigated and quan-
titated for other species. Therefore, no actual relative CYP distribution pro-
file for other species cannot be demonstrated. Surprisingly, mouse and rab-
bits are perhaps the less studied species in this respect (see [16]).
3.2. Effect of diagnostic inhibitors
Major qualitative species-dependent differences have been described
in general pharmacological and toxicological text books demonstrating
that some basic metabolic reactions can be even species restricted ones.
Moreover, although sequence homology of CYP enzymes between spe-
cies is considerably high, amino acid mutations in their active center can
result in remarkable substrate specificity and/or reaction velocity diffe-
rences and wide variation in their response to chemical inhibitors. As an
example of that ketoconazole has its main inhibitory potential against hu-
man microsomal CYP3A4 and also in a lesser potency for CYP1A1/2,
2C9 and 2D6 [17]. However, no such inhibition can be found in beagle
dog microsomes against CYP1/2, 2C12 and 2D15 [18]. In rat at 10 µM
concentrations considerable inhibition of CYP1A2 and 2C6 in addition
of “diagnostic” CYP3A1 and 3A2 inhibition was found [19]. Moreover,
in rat cDNA-expressed P450s system out of seven “diagnostic for human
CYPs” inhibitors only sulfaphenazole can be considered as a selective in-
hibitor for rat CYP2C6 [19]. Therefore, what is “diagnostic” for one spe-
cies may not be adopted across the species.
3.3. Regulatory platform
Overall pharmacokinetic characteristics of a new chemical entity have
been for a long time the most crucial factor for its coming success in a
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drug development program. In this respect, predictability of drug meta-
bolism in non-clinical studies is of major value. At present several re-
combinant-based alternatives are available to study metabolism of a drug
molecule in vitro. However, still the basic pharmacokinetic and toxicoki-
netic evaluations have to be carried out in different animal models in vivo.
According to the up-to-date regulatory guidelines these animal models
should be based on the “best fit model” to mimic physiology, disease pa-
thology and the metabolic characteristics of man.
It is well known that species differences, both qualitatively and quan-
titatively, in drug metabolizing pathways are genetically determined. The-
refore, to find the “best fit” model may not be an easy task to resolve. It
has even been suggested that a priori knowledge of metabolizing enzy-
mes gives no guide in identifying the failure or success of allometry for
prediction of clearance [20]. I wonder if this claim can be widened to
pharmacological and toxicological responses, too.
4. EXAMPLES OF SPECIES-DEPENDENT INDUCIBILITY OF
CYP ENZYMES
Remarkable species-dependent differences in the inducibility of drug
metabolism and mechanisms behind the phenomena can be found. A few
examples will be highlighted at a very general level only; induction of
CYP1A and CYP3A in vitro and in vivo.
Polycyclic aromatic hydrocarbons (PAH), 3-methylcholantrene and
benzoflavone are effective inducers of CYP1A enzyme throughout the
species when assayed by 7-ethoxyresorufin O-deethylase [21, 22], i.e.
CYP1A1 induction seems to be a universal phenomenon. Interestingly,
oral PAH are more effective inducers of minipig duodenal CYP1A than
the hepatic form which follows just an opposite pattern reported in rats
[22]. On the other hand, omeprazole produces a “human like” CYP1A in-
duction in the dog, rabbit and minipig hepatocytes while rat, mouse and
monkey hepatocytes are reasonably resistant to the effect of omeprazole
(23, 24; Table 2).
CYP3A inducibility follows also both inducer and species-de-
pendent pattern. In in vitro test system human and rat CYP3A res-
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ponses to rifampin and dexamethasone are opposite. Comparison of
dexamethasone and rifampin in the induction of CYP3A activity in
rat, dog, pig and human hepatocytes demonstrated that rifampin is the
most potent inducer of CYP3A in human hepatocytes in vitro follo-
wed by dog > pig but in rat hepatocytes it is not an inducer at all
(Table 3). Instead, dexamethasone seems to be a more potent inducer
of rat CYP3A. Moreover, in dogs the induction was more potent in
males than females. In pigs no such sex-linked differences was ob-
served [24].
Autoinduction of metabolism caused by the drug under investiga-
tion may also complicate predictability from animal metabolism data to
humans. Voriconazole is an example with its nonlinear pharmacokine-
tic characteristics. Autoinduction is not observed in humans but multi-
ple dosing of voriconazole results in substantially decreased exposure
levels in mouse and rat, less decreased in dog and not at all in quinea
pig or rabbit [25].
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TABLE 2
The effect of omeprazole and 3-methylcholanthrene on CYP1A mRNA
or enzyme activity (EROD) in vitro
Species Omeprazole 3-Methylcholanthrene
Human ++ ++
Rat (+) +++
Mouse ?? (high conc) ++
Rabbit ++ +++
Monkey ?? (high conc) ++
Dog ++ ++
Mini pig ++ ++
(+), marginal induction; ++, < 10 fold dose and time dependent increase; +++, > 10 fold increase
in the parameter studies, ?? induced by high concentrations only. Data from [23, 24]
5. GENERAL OVERVIEW- CYP EXPRESSIONS IN
SELECTED SPECIES
5.1. Monkey
Cynomolgus monkeys express constitutively CYP1A, 2A, 2B, 2C and
3A proteins similar to man but the enzymatic profile in vitro using alkoxy-
resorufin derivatives as diagnostic probe substrates is more close to the pro-
file obtained in rat than man [21]. Moreover, considerable differences in the
total P450 content and specific immunoreactive CYP protein in hepatic mi-
crosomes from nonhuman primates has been described [26]. It has been de-
monstrated that a monoclonal antibody against human CYP3A4 can specifi-
cally differentiate human and Rhesus monkeys CYP3A proteins from mouse,
rat and dog counterparts [27] and that in African green monkey CYP2A6 me-
diated nicotine metabolism mimic human situation [28]. Moreover, pheno-
barbital has been shown to increase CYP2B6 immunoreactive protein in Afri-
can green monkey [28]. Therefore, because of their similar CYP profile,
monkeys in general can be considered a species of choice in drug metabo-
lism studies. However due to ethical considerations the use of primates may
not be the first option in the ranking list when selecting the species for the
first pharmacokinetic evaluations. In drug development program the selec-
tion of species has to be put in the perspective with both the chemical and
indication under study.
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TABLE 3
The effect of rifampin, dexamethasone and phenobarbital on human,
minipig, beagle dog and rat hepatocyte CYP3A activity in vitro
Species Rifampin Dexamethasone Phenobarbital
Man ++++ + +++
Minipig ++ – ??
Beagle dog ++ – ??
Rat (+) +++ ++
(–) no induction; (+) marginal induction; (++) medium induction; (+++) strong induction; (++++)
very strong induction; (??) not studied.
Data from [24, 78, 79]
5.2. Dogs
In beagle dogs CYP families 1A, 2A, 2B, 2C, 2E and 3A are ex-
pressed [7, 18, 29]. Interestingly, in one comparative study of CYP2C
proteins using tolbutamide hydroxylation assay as a probe the activity
could not be detected in dog microsomes [29] but after phenobarbital in-
duction a protein, an N-terminal amino acid sequence of which resem-
bles CYP2C protein, has been purified [30]. In dogs phenobarbital, ri-
fampin, 3 methylcholanthrene and b-naphthofalvone were the most potent
inducers of the total CYP450 content in vivo. Unfortunately, no other spe-
cies was used as a reference to compare the potency of induction and pro-
file of CYP enzymes involved. Two bands in Western blotting were de-
tected after b-naphthofalvone induction, a well-known inducer of CYP1A
enzymes. The expression of CYP2B11 was increased after phenobarbital
treatment but no effect after ethanol treatment on 4-nitrophenol hydroxy-
lase or chlorzoxazone 6-hydroxylation activites was found. Rifampicin
and phenobarbital enhanced testosterone 6b- hydroxylase activity ex vivo
and in vitro, both of them affecting the expression of CYP3A12 [7]. Whe-
ther, CYP2C and 2E1 proteins are expressed at basal level in dogs seems
to depend on experimental conditions and methodology used.
A good example for species-dependent enantiomer specific metabolism
is dog-associated stereoselective metabolism of bisoprolol. In dogs biso-
prolol is extensively metabolized by both high affinity CYP2D and low-af-
finity CYP3A enzymes; with the overall R(+)/S(-) ratio of 1.46 favoring
the R isomer while in humans stereosectivity is performed only via the low-
affinity CYP2D form that represents only for less than 5% of the metabo-
lism of bisoprolol in man [31]. Suggesting that in man stereoselectivity has
no clinical value. On the other hand, in baculovirus expressed CYP pro-
teins dog enzymes catalyzed dextromethophan O-demethylation and N-de-
methylation by CYP2D15 and 3A12, orthologus to human CYP2D6 and
3A4 [32], thus mimicing human metabolic characteristics. In general dog
is a good alternative model for drug metabolism studies.
5.3. Pig
Pig and mini/micropig is increasingly used in pharmacokinetic and
toxicity studies. Its use is relevant; it is omnivore as man and the pig
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is suggested to be the species of choice for hepatocyte xenograft in hu-
mans. However, thus far characterization of CYP enzyme profile in
pig/minipig has resulted in contradictory CYP expression results. Es-
pecially problematic is CYP2D expression. In one study all main CYP
activities excluding 7-pentoxyresorufin O-dealkylation (CYP2B) were
detectable in reasonable quantity in mirosomal fraction of minipig li-
ver [33]. In the other studies [34-36] CYP 2C and 2D linked enzyma-
tic activities could not be detected reliably, although the CYP2D25
gene with 75% homology with the human 2D6 has been identified in
pig liver. In addition, swine homologs to CYP1A, 2B and 2E posses
different molecular weight from their rodent and human counterparts
[37]. In further studies a human cDNA could detect a CYP2D6-like
mRNA and positive immunoreactive protein was found from pig he-
patocytes [38].
Pig microsomes do not metabolize debrisoquine. Instead pig mi-
crosomes metabolize dextromethorphan with a biphasic kinetics, and
bufuralol, but once again no correlation between these two enzyma-
tic activity and CYP2D protein could be demonstrated [38, 39]. Ins-
tead, a positive correlation with CYP2B immunoreactive protein con-
tent and an inhibitory response to chemical inhibitors of CYP2B was
observed [39]. Moreover, remarkable sex-dependent differences in
CYP1A and 2E enzymes was observed [35]. The basal activities of
CYP1A are reported to be 6- fold, CYP2A 6-fold and CYP2C 3
—fold higher in human liver microsomes compared to minipig enzy-
mes levels. On the other hand “CYP2D-linked” activity was 4-fold
higher in minipig liver microsomes compared to that obtained in hu-
man liver microsomes [33]. Due to these extremely contradictory re-
sults (missing activities, different molecular weights) more confir-
matory studies are needed to validate pig for CYP2D panel. Probably
this discrepancy is due to pig strain differences [34, 35]. On the other
hand minipig has been shown to be a reasonable good model for al-
cohol-induced liver damage in man [40] and polycyclic aromatic
hydrocarbon contaminated soil has been demonstrated to induce
CYP1A expression in hepatic and extrahepatic tissues in minipigs af-
ter oral exposure [22] thus mimicking cicarette smoke induction of
CYP1A in man [41].
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6. SPECIES-DEPENDENT EXPRESSION OF CYP ENZYMES
6.1. Comparative studies within the CYP1A enzymes
CYP family 1A is the most conserved amongst all. Their substrates
are common throughout the species; mainly planar polycyclic aromatic
hydrocarbons for CYP1A1/2. According to the microsomal fraction in vi-
tro enzymatic data throughout the species (mouse, rat, rabbit, dog, mi-
cropig, monkey, man) 7-ethoxyresorufin O-deethylation is characteristic
for this enzyme. Other relevant marker activities are dealkylation reac-
tions of other alkoxyresorufin derivatives, phenacetin O-deethylation,
acetanilide 4-hydroxylation and N-hydroxylation reaction of several he-
terocyclic amines.
Remarkable species-dependent differences can be observed in the me-
tabolic capacity towards the substrates listed above. For example, ethoxy-
resorufin O-deethylase activity was inhibited by 80 –100% by human anti-
CYP1A antiserum and a-napthoflavone in mouse, rabbit, dog and human
liver microsomes, but only moderately in rat, micropig and monkey liver
microsomes [3]. Furafylline which have considered to be preferentially
CYP1A2 specific inhibitor in human liver microsomes [42, 43] produced
a very strong inhibition only in human samples, moderate or even less
inhibition in rat, mouse, rabbit and dog microsomes and did not inhibit
at all in monkey and micropig microsomes [3]. Representative examples
concerning CYP1A enzymatic activities in different species from com-
parative studies is shown in Table 4.
Although catalytic characteristics of CYP1A subfamily are quite well
conserved throughout the species, still some species-dependent differen-
ces in the substrate specificity of CYP1A can be found. For instance, rat
CYP1A2 protein is more active in 7-methoxyresorufin O-deethylation
than the human counterpart but the human CYP1A2 was more active in
the N-hydroxylation of 2-amino-3,8-dimethylimadozo(4,5-f)quinoxaline
(MeIQ) [1]. In another comparative study on CYP1A2 linked procarci-
nogen activation of 2-amino-3-methyl-imidazole(4,5-f)quinone was the
most active in rats followed by monkey > dog=human microsomes. Ho-
wever, antibody sensitive responses followed the order human=rat > dog
> monkey [44]. Studies with anti-human CYP1A antibody and chemical
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inhibitor (a-naphthoflavone) have resulted remarkable interspecies diffe-
rences and picked up a group of species in which a similar inhibitory po-
wer in 7-ethoxyresorufin O-deethylase activity was obtained. Similar in-
hibitory characteristics were obtained in mouse, rabbit, dog and human
liver samples [3]. It is worthy to emphasize that thus far no real compa-
rison between species and enzyme sources with all suggested substrates
of CYP1A subfamily have been carried out. Therefore, real interspecies
differences still remain to be resolved.
Antibodies against distinct CYP proteins, both diagnostic and inhibi-
tory ones, and the results obtained differ remarkably between laboratories.
An antibody against human CYP1A2 recognizes antigenic determinants in
cynomolgus monkey and beagle dog microsomes but, interestingly, not in
Sprague-Dawley rat liver microsomes [5]. However, monoclonal antibody
against 3-methylchoanthrene-induced CYP1A in rat recognizes an ortholo-
gous form across the species in different test systems [45]. Interestingly, an
anti-human CYP1A antibody has been shown to influence on dog micro-
somal CYP2E1 mediated chlorzoxazone 6-hydroxylation [3].
Although primates in general have been considered more closely mimic
CYP enzymes in man, still some differences exist. Based on heterocylic ami-
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TABLE 4
Representative examples of CYP1A associated enzymatic activities
in different species and laboratories.
Phenacetin Ethoxyresorufin O-deethylation
Species O-deethylation [80] [36] [3]
Ref. [5] pmol/min/mg protein
Human 32±30 21±14 18.3±6.5 95 m; 25 f 
Monkey 110±20 240±85 ND 129 m; 118 f
Dog 28±10 46±25 23.1±3.9 409 m; 411 f
Guinea pig 172±20 ND
Rat 36±20 ND 31.1±10.9 78 m; 67 f
Pig/minipig ND ND 5.4±2.1 57 m; 116 f
ND, not determined; f, female; m, male
ne N-oxidation studies [46] cynomolgous monkeys have been found to be
defective for CYP1A2 enzyme. On the other hand, it has been shown that
chronic exposure of cynomolgus monkeys to IQ induce hepatic microsomal
CYP1A1 and CYP1A2, and CYP3A and CYP2C being the principal forms
associated with metabolic activation of IQ [47]. Obviously this will restrict
the use of this species in CYP1A2 linked metabolism and toxicity studies.
6.2. Comparative studies within the CYP2A
CYP2A protein was originally purified from pyrazole-induced mouse li-
ver microsomes [48]. CYP2A -linked metabolic characteristics have been
intensively studied in man, rabbit, rat monkey, hamster and human tissues
and subcellular organelles. It became clear that these proteins differ subs-
tantially in catalytic specificity and inducibility between the species and
evens strains [49]. However, still one common denominator exists; all
CYP2A proteins catalyze coumarin 7-hydroxylation reaction with a varia-
ble intensity (Table 5). However, one exception exists. In the rat liver, the
CYP2A3 gene is not virtually expressed and coumarin 7-hydroxylation ac-
tivity is negligible [3, 50, 51]. Unlike in mouse, the gene was not inducible
in rat liver by 3-methylcholanthrene or pyrazole [51]. On the other hand,
dispite the immunological and catalytical similarities between mouse and
hamster CYP2A enzymes in hamsters 3-methylcholantrene does not enhan-
ce the expression of CYP2A and pyrazole decrease CYP2A expression and
sex-oriented expression pattern is opposite between the two species [52, 53].
Among the important toxicity study species the coumarin 7-hydroly-
lase activity is the lowest in dog hepatic microsomes and highest in mou-
se, rabbit, monkey and human liver microsomes [3, 54]. The reaction ve-
locity is comparable between human and African green monkey
microsomes but still immunological and chemical inhibitor-dependent
species differences can be obtained [54] demonstrating that the proteins
in these two species are not identical.
Remarkable species-dependent differences in inhibition of coumarin 7-
hydroxylase activity between mouse and human have been observed. Com-
pared to other CYP mediated reactions pilocarpine was a reasonably se-
lective inhibitor (Ki <1 mM) for mouse and human coumarin 7-hydroxylase
and of similar potency [55, 56]. However, metyrapone is two orders of mag-
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nitude more potent inhibitor for mouse than human CYP2A [57]. Compa-
rative molecular field analysis and in vitro inhibition studies demonstrated
that naphthalene is competitive inhibitor in vitro both for mouse and hu-
man hepatic coumarin 7-hydroxylase with the Ki of 12-26 and 1,2 –5.6 mM
[58], respectively. 5- or 6-position substituted g and d- lactones are potent
inhibitors for mouse CYP2A5 but not for human CYP2A6 [59].
Based on the above examples it can be concluded that with respect
of CYP2A linked (coumarin 7-hydroxylation) metabolism the “best fit”
models are mouse, dog, pig, and monkey.
6.3. Comparative studies within the CYP2B
In humans the only representative of this family is CYP2B6, the expe-
ssion of which is less than 1% of the total hepatic CYP pool [60] with more
than two order of magnitude interindividual variation in bupropion hydroxy-
lation velocity [61]. Other possible substrates (used in other species, such as
mouse, rat, rabbit, dog, monkey and human [1] are phenoxazone derivatives,
7-ethoxycoumarin, 6-aminochrysene, 3-methoxy-4-aminoazobenzene and ni-
cotine [60-63].
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TABLE 5
Representative examples of CYP2A associated coumarin 7 hydroxylase
activity determinations in different species and laboratories
Coumarin 7-hydroxylation
Species Ref. [5] [36] [3]
(pmol/min/mg protein)
Human 21±12 617±256 1275 m; 357 f
Monkey 209±126 ND 2398 m; 7175 f
Dog 12±5 6.5±5.9 68 m; 180 f
Guinea pig 20±8 ND ND
Rat <1 1.2±0.4 <5 m/f
Pig/minipig ND 16.6±7.9 18 m; 966 f
ND, not determined; f, female; m, male.
In other species than man several active forms are expressed: rat, 2B1,
2B2; rabbits 2B4, 2B5; dog 2B11 and one 2B form in monkey with a
high testosterone hydroxylation activity [26]. For instance, in beagle dogs
a 13-fold increase in pentoxyresorufin O-dealcylase activity after pheno-
barbital induction was seen [7].
However, no comparative study using the same validated methodo-
logy has been carried out to resolve species-dependent differences in ca-
talytic characteristics of CYP2B enzymes with the above mentioned subs-
trates. Therefore, no clear ranking between species can be carried out.
6.4. Comparative studies within the CYP2C family
CYP2C family comprises about 20% of total hepatic P450s in humans
and four representatives of 2C enzymes have been characterized (2C8,
2C9, C18, 2C19) with >80% identical amino acid sequences. Marker ac-
tivity for polymorphically expressed CYP2C8 in humans is paclitaxel 6-
hydroxylation [64]. Based on enzyme classification or substrate specifi-
city studies no such counterpart has been identified experimental animals.
Marker activities for CYP2C9 are S-warfarin 7-hydroxylation and tol-
butamide methyl hydroxylation reactions [65], for CYP2C19 S-me-
phenytoin 4-hydroxylation and tolbutamide methyl hydroxylation [66].
In animals a huge species-dependent differences within this family
can be observed (Table 7). The lowest catalytic mephenytoin 4’-hydroxy-
lase determinations were recorded in minipigs [3]. In rats eight CYP2C
forms are expressed with remarkable gender, growth hormone and other
circadial rythm-linked factors affecting their expression [67-69]. For
example, based on in vitro assays and antibody inhibition experiments the
N-oxidation of irsogladine is catalysed by CYP2C proteins in rat, dog and
monkey microsomes but no significant metabolism was obtained by hu-
man microsomes or recombinant CYP2C9 protein [70].
As a recent example of species-dependent CYP2C differences is meta-
bolism of (-)-verbenone. In the rat, the male-specific CYP2C11 was a ma-
jor enzyme in (-)-verbenone 10-hydroxylation by untreated rat livers, and
CYP2B1 catalyzed this reaction in liver microsomes of phenobarbital-trea-
ted rats. A female-specific enzyme, CYP2C12 did not catalyze (-)verbeno-
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ne 10-hydroxylation. Human recombinant CYP2A6 and CYP2B6 catalyzed
(-)verbenone 10-hydroxylation at Vmax values of 15 and 21 nmol/min/nmol
P-450 with apparent Km values of 16 and 91 mM. Rat CYP2A1 and 2A2
did not catalyze (-)-verbenone 10-hydroxylation at all [71].
In rabbits 2C enzyme profile is even more complicated; nine forms
(2C1, 2C2, 2C3, 2C4, 2C5, 2C14, 2C15, 2C16, 2C30) have been identi-
fied (www.icgeb.org/~p450srv/P450Nom_Animals_2.html#CYP2C). In
rabbit CYP2C protein(s) catalyses testosterone 6b-hydroxylation. Ob-
viously multiplicity of CYP2C forms in rabbits is compensatory to re-
place the wide catalytic flexibility of CYP3A4 in human liver.
S-mephenytoin has been used as a probe for human CYP2C19. In-
terspecies comparison (mouse, rat, rabbit, dog, monkey, human) demons-
trated that microsomal 4-hydroxylation of R-enantiomer was 2 to 6 times
higher in rabbits, dogs and rats compared to S-enantiomer hydroxylation
rates. Preferential, a human-like, S-mephenytoin 4-hydroxylation was ob-
tained only with monkeys [72]. Representative examples concerning
CYP2C enzymatic activities in different species is shown in Table 6.
Due to multiple genes in animals CYP2C proteins have obviously ta-
ken some stake holding properties which are linked CYP3A4 in man. Mo-
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TABLE 6
CYP2C associated mephenytoin 4’-hydroxylation in different species
and laboratories
Mephenytoin 4’-hydroxylation
Species Ref. [5] [3]
pmol/min/mg protein
Human 39±23 19.8m; 9.6 f
Monkey 144±26 23 m; 19.7 f
Dog 106±13 3.2 m; 5 f
Guinea pig 139±17 ND
Rat 74±15 1.6 m; 0.6 f
Minipig ND < 0.4 m; < 0.3 f
ND, not determined; f, female; m, male
reover, the sex-dependent expression CYP2C proteins in several species
complicate interpretation of any animal CYP2C data across the species
and to humans. The low catalytic mephenytoin 4’-hydroxylation may de-
crease the value of minipig in CYP2C linked metabolic studies.
6.5. Comparative studies within the CYP2D
Due to clinically relevant interactions with several crucial drugs, such
as cardiovascular and psychotrophic drugs, and a well-known pharmaco-
genetic polymorhism, this form in humans is under special focus. If a
drug candidate demonstrates interactive potential towards this protein it
may be a reason to discard the molecule from further development.
Humans have only one catalytically active polymorphically expres-
sed form CYP2D6. It represents about 4% of total P450 content in the
human liver. In rats four genes (2D1-4) have been identified but, for ins-
tance, their overall amount in rat’s hepatic total P450 pool is still unre-
solved. Moreover, catalytic characteristics or responses to chemical inhi-
bitors of rat CYP2D forms have not been studied in details.
In a comparative study [3] using bufuralol 1-hydroxylase activity as
a probe for the enzyme remarkable species-dependent differences were
observed. The species were divided into two groups; dog and man having
similar enzyme kinetics and quinidine inhibition profiles compared to the
rest tested: mouse, rat, rabbit, micropig and monkey [3].
Interestingly, rabbit genome does not contain any gene corresponding
to human CYP2D6 [73]. Representative examples concerning CYP2D
enzymatic activities in different species is shown in Table 7.
In primates several CYP2D proteins have been identified. For ins-
tance, from Japanese monkey liver a 497 amino acid protein (CYP2D29)
shared 96, 91 and 88 % homology with human CYP2D6, cynomolgus
monkey CYP2D17 and marmoset monkey [74]. CYP2D29 content was
considerably higher in Japanese monkey liver microsomes than CYP2D6
in humans. Km values of bufuralol 1-hydroxylations were comparable
between CYP2D6 and 2D29 but the Km value for debrisoquine hydroxy-
lation was much lower in Japanese monkey CYPD29 compared to hu-
man CYP2D6 [74].
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Based on the date above the most human-like CYP2D responses can be
obtained by dog microsomes. The use of pig or minipig microsomes or he-
patocytes as a denominator for CYP2D linked reactions is still under debate.
6.6. Comparative studies within the CYP2E
According to the study of Court et al (1997) [75], based on the chlor-
zoxazone 6-hydroxylation activity determinations, CYP2E1 is quite well
conserved throughout the species. A single-enzyme Michaelis-Menten
model was obtained for cat, cow, dog, horse, human, mouse and rabbit
microsomal samples but a two-enzyme model was obtained for ferret,
monkey, pig and rat. Moreover, diethyldithiocarbamate was a potent me-
chanism-based inhibitor of 6-OH- chlorzoxazone formation in all species
studied. [75]. However, the results from Bogaards et al. [3] did not sup-
port this conclusion in which 10-fold species-dependent differences in the
chlorzoxazone 6-hydrolation were observed, and an anti rat CYP2E1 an-
tibody did not inhibit chlorzoxazone 6-hydrolase activity in micropig mi-
crosomes [3]. However, a monoclonal antibody against rat CYP2E1 de-
tects a CYP2E counterpart in immunohistochemistry [40]. In conclusion,
this suggests that pig may not be the optimal animal model for CYP2E1
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TABLE 7
CYP2D associated bufuralol 1’-hydroxylation in different species
and laboratories
Bufuralol 1’-hydroxylation
Species Ref. [5] [3]
(pmol/min/mg protein)
Human 20±14 151 m, 87 f
Monkey 471±58 1167 m; 955 m
Dog 12±2 191 m; 260 f
Guinea pig 29±14 ND
Rat 743±74 1021 m; 596 f
Minipig ND 653 m; 638 f
ND, not determined; f, female; m, male
mediated reactions. More comparative studies with substrates, diagnostic
inhibitors and antibodies will be needed to resolve this discrepancy.
6.7. Comparative studies within the CYP3A
Testosterone 6b-hydroxylation reaction has been used as a marker for
CYP3A4 in human tissues. CYP3A4 and rat 3A12 share 79% amino acid se-
quence similarity but still - based on antibody studies - their active sites seem
to be substantially different. As an example is the metabolism of dexametha-
sone in mouse, rat, quinea pig, hamster and human liver microsomes in vitro.
Remarkable qualitative and quantitative species-dependent differences were
observed. Potency of ketoconazale inhibition varied according to species so
that it cannot be regarded as a selective inhibitor of CYP3A enzymes in all
species [76]. On the other hand nifedipine hydroxylation and testosterone 6b-
hydroxlylation activities are comparable between man and minipig but inhi-
bition potency of nifedipine oxidation by triactyloleandromycin was conside-
rably lower in minipig microsomes than in human samples [33]. In dogs
testosterone 6b-hydroxylase has been reported to be one eight of that obtai-
ned by human microsomes [29]. Representative examples concerning CYP3A
enzymatic activities in different species and substrates are shown in Table 8.
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TABLE 8
CYP3A associated enzymatic activities (erythromycin N-demethylation,
testosterone 6ß hydroxylation and nifedipine oxidation) in different species
Species
Erythromycin Tb-OH Nifedipine oxidation
N-demethylation
(pmol/min/mg protein)
Human 244±212 5307 m; 8997 f 605±691
Monkey 586±101 11941 m; 10764 f 3826±131
Dog 144±70 1488 m;1656 f 456±126
Guinea pig 500±65 ND 2990±815
Rat 930±164 3396 m; 378 f 820±187
Minipig ND 4852 m; 4116 f ND
Erythromycin N-demethylation [5]; testosterone 6b hydroxylation [3]; nifedipine oxidation [36];
ND, not determined.
7. CYP ENZYMES AND TESTOSTERONE HYDROXYLATIONS
Testosterone 6b-hydroxylation reaction is generally used for
CYP3A determinations in man. Moreover, numerous other testostero-
ne hydroxylation reactions are catalyzed by the other CYP enzymes.
Table 9 summarizes briefly major testosterone hydroxylation products
and CYP forms mainly catalyzing the reactions according to species.
It can be seen that depending on the species several unresolved acti-
vities exists. Further analysis with rat, pig, rabbit, dog and human he-
patocytes has demonstrated [36] that according to the total qualitative
and quantitative steroid hydroxylation profile the “best-fit” animal mo-
dels are pig and dog. Total testosterone metabolite profile was in tho-
se species mostly “human-like” both quantitatively and qualitatively.
In rat and rabbit hepatocytes remarkable deviation was observed. Un-
fortunately, monkey microsomes or hepatocytes were not included in
the study.
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TABLE 9
Testosterone hydroxylation reactions and the main catalyzing CYP
forms in microsomal fractions from man, rat, rabbit, dog and pig
Testosterone
Hydroxylation Man Rat Rabbit Dog Pig
15b 3A4 3A1 ? ? ?
6b 3A4 1A1/2 2C3, 3A6 3A12 3A
7a ND 2A1 ND ND ND
16a ? 2B1,2C11 2B4 2C21 ?
16b 2C9 2B1 ? 3A12 ?
2a ND 2C11 ND 3A12 ND
2b 3A4 ND ? 3A12 ?
Formation of Isomerase 2B1,2C11 ? ? ?
androstenedione
(??) activity detectable, but the CYP form catalysing the reaction has not been identified. ND, not
detectable; (modified by the author from [32, 36]; and based on the references in the article and
www.xenotechllc.com)
8. CONCLUDING REMARKS
According to the present date the selection of optimal model to mi-
mic metabolism in man based on CYP enzymes only is not an easy
task. As a general remark CYP1A and CYP2E associated activities and
responses are more generalized that those of other CYPs. Especially
wide variation in catalytic responses is within the CYP2C proteins.
They are expressed in multiple forms and some of those are under sex
hormone or growth hormone regulation. Obviously all the data obtai-
ned by rat is relevant but still it remains uncertain weather it is the op-
timum model for man. Via transgenic and knock- out mouse models
the importance of mouse pathologists and overall understanding of
mouse xenobiotic metabolizing enzymes has increased. Still, characte-
rization of the xenobiotic-metabolizing pathways in mouse is far form
the details reported for rat. Pig or minipig, is an interesting alternati-
ve for rodents in toxicological studies but yet their documentation in
terms of CYP, for instance, and scientific basis is far from the tradi-
tional rodent ones. Especially warranty should be considered if CYP2C,
CYP2D or 2E are involved in the metabolism of a compound under in-
vestigation. Hamster and rabbit seem to be far from any validated mo-
del for CYP panel. On the basis of the testosterone metabolizing CYP
activity profiles dog and pig seem to be relevant species to mimic CYP
enzymes in man.
In conclusion: More comparative studies with validated methodology
are needed to resolve species-dependent differences in catalytic charac-
teristics; inhibitions with different antibodies, reaction kinetics with
“diagnostic” substrates and chemical inhibitors e.t.c. To this aim a global
“interspecies CYP test panel tool box” should be established and syste-
matically evaluated in order to facilitate comparisons of the results ob-
tained in different laboratories and species, and, especially in the inter-
pretation the obtained result to man.
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